Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | USP2 | O75604 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.68 |
| ▸ | HTR3B | O95264 | 2/20 | 0.68 |
| ▸ | HTR3A | P46098 | 2/20 | 0.68 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.68 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022113 | 1.00 | HTR7 (1.00) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL30146627 | 0.98 | HTR7 (0.96) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL29157433 | 0.98 | HTR7 (0.96) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6786785 | 0.98 | HTR7 (0.96) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL13118661 | 0.86 | HTR7 (0.76) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL15577989 | 0.86 | HTR7 (1.00) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL15538190 | 0.86 | HTR7 (0.75) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL13118660 | 0.84 | HTR7 (0.81) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL1359864 | 0.82 | ADRB1 (0.76) | HTR7HTR1ATP53CYP1A2CYP2D6 | |
| SCHEMBL27497441 | 0.82 | HTR1A (0.70) | HTR7HTR1ATP53CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| CN-113272292-B | (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases | 雅盖隆大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117586179-A | GPR183 antagonist and synthetic method and application thereof | 中国人民解放军海军特色医学中心 | 2024-02-23 | — | — | CN | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-0931067-B1 | D4 RECEPTOR SELECTIVITY PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-6258813-B1 | BIOLOGICAL RECEPTORS WITH TETRAHYDROPIPERIZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT (DE) | 2001-07-10 | — | — | US | disclosed |
| EP-0931067-A1 | D4 RECEPTOR SELECTIVITY PIPERAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998011068-A1 | D4 RECEPTOR SELECTIVITY PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1998-03-19 | — | — | WO | disclosed |
| US-4831034-A | 4-benzylpiperazines useful as neuroleptics | RHONE-POULENC SANTE (FR) | 1989-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | HTR7 3241/4885HTR1A 3924/4885TP53 4565/4885 |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | HTR7 2576/4885HTR1A 3731/4885TP53 2811/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | HTR7 4806/4885HTR1A 4682/4885TP53 2252/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HTR7 4826/4885HTR1A 4709/4885TP53 1678/4885 |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | HTR7 1802/4885HTR1A 2645/4885TP53 79/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | HTR7 4142/4885HTR1A 3787/4885TP53 120/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | HTR7 4280/4885HTR1A 4572/4885TP53 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.